Chemo-sensitivity & Genomic Tests
CHEMO-SENSITIVITY & GENOMIC TESTS
(molecular cancer diagnostics)
Chemo-sensitivity and genomic testing are useful when the patient uses chemotherapeutic agents and even some supplements. These tools can help to individualized protocols thereby finding the most effective and safest pharmaceutical and neutraceutical interventions. (1) These tests can be ordered via the links below:
1. The Greek RGCC test has a 2 week turnaround time. It can cost $2700 – $3000 depending on the exchange rate and is not usually reimbursable by insurance.
2. Biofocus (“German Test”) is similar as the Greek one. Its costs is about $3000. See this link for some of the science that supports this detection modality.
3. Dr Nagourney in California proposes a smilar tests, but for more expensive, at around 4000 dollars. Furthermore, Dr Nagourney only tests the primary tumor and usually required a large biopsy.
(1). One of the problems with conventional oncology is that the doctors have used a “one-size-fits-all” approach and therefore the drugs too often fail with life altering consequences. With chemo-sensitivity and genomic testing, some semblance of “precision” and individualized medicine is achieved. The personalized approach is to identify the circulating Tumor Cells, (CTCs) and Cancer Stem Cells (CSCs) to see what natural and chemical substances they are most sensitive to. The procedure consists in remove some of the patient’s blood which can then be harvested so that cancer cells and the cancer stem can be grown in petri dishes, where various pharmaceutical and natural substances are introduced. After 48 hours, each substance is measured to see how effective it is in terms of cancer cell and cancer stem cell apoptosis or necrosis. In this realm, the most popular test is the GreekTest which checks 49 chemo drugs and 50 natural biologic substances such as enzymes, Poly MVA, Vitamin D3, fermented soy extract, mistletoe, SOD, burdock complex, B 17. The patient also have the option of sending 2 specific natural substances that are not on the Greek test list. Based on the results of the test, the practitioner can learn the following: (a) which specific genes are involved in the growth of the cancer, (b) the effectiveness of drugs and natural substances. Thanks to this data, a precise and individualized protocol can be ascertained. Sloane Kettering and the University of Texas MD Anderson Cancer Center in Houston are beginning to use the test after have received a $15 million dollar grant from the Stand up to Cancer Telethon. For more details, see this Source.